| Systematic (IUPAC) name | |
|---|---|
| Thiazol-5-ylmethyl N-[1-benzyl-4-[[2-[[(2-isopropylthiazol-4-yl)methyl-methyl-carbamoyl]amino]-4-morpholino-butanoyl]amino]-5-phenyl-pentyl]carbamate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 1004316-88-4 |
| ATC code | ? |
| ChemSpider | 25084912 |
| UNII | LW2E03M5PG |
| Chemical data | |
| Formula | C40H53N7O5S2 |
| Mol. mass | 776.023 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Cobicistat is a drug under experimental investigation for use in the treatment of infection with the human immunodeficiency virus (HIV).
Like ritonovir (Norvir), cobicistat is of interest not for its anti-HIV properties, but rather its ability to inhibit liver enzymes that metabolize other medications used to treat HIV, notably elvitegravir, an HIV integrase inhibitor currently under investigation itself. By combining cobicistat with elvitegravir, higher concentrations of elvitgravir are achieved in the body with lower dosing, theoretically enhancing elvitgravir's viral suppression while diminishing its adverse side-effects. In contrast with ritonavir, the only currently approved booster, cobicistat has no anti-HIV activity of is own.[1]
If approved by the U.S. Food and Drug Administration, cobicistat will be part of the four-drug, fixed-dose combination HIV treatment known as the "Quad Pill".[1][2] The Quad Pill is currently in Phase III clinical trials,[3] and is owned by Gilead Sciences.